Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Psoriatic Arthritis | Unmet Need | US/EU | 2024

Login to access report north_east
Contact sales account_box

TNF-alpha inhibitors remain the primary choice for psoriatic arthritis (PsA) after conventional DMARD failure, howeverbut competing biologics such as IL-17 inhibitors (Cosentyx, Taltz, Bimzelx), IL-12/23 inhibitors (Stelara), IL-23 inhibitors (Tremfya, Skyrizi), and targeted oral therapies such as PDE4 inhibitors and selective JAK inhibitors (Otezla, Xeljanz, Rinvoq) are increasingly challenging the dominance of TNF-alpha inhibitors in treating PsA. Moreover, many patients do not respond adequately to these agents, necessitating alternative treatment strategies. Thus, rRecognizing gaps in PsA treatment and focusing on product differentiation may play a crucial role in an agent’s success in this competitive PsA space. This report outlines key unmet needs and offers tools for strategic decision-making in the PsA therapy market.

QUESTIONS ANSWERED

  • How do current therapies perform on key treatment drivers and goals for PsA?
  • When considering Humira, Cosentyx, Taltz, Otezla, Rinvoq, Bimzelx, Skyrizi, and others wWhich drug attributes are key influencers, which have limited impact, and which are hidden opportunities in PsA?
  • What are the prevailing areas of unmet need and opportunity in the PsA market?
  • What trade-offs across key drug attributes and price are acceptable to rheumatologists and dermatologists for a hypothetical new PsA drug?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 31 European rheumatologists and dermatologists fielded in DecemberFebruary 2024

Key companies: AbbVie, Amgen, UCB, Pfizer, Johnson & Johnson Innovative Medicine, Novartis, Eli Lilly

Key drugs: Humira, Cosentyx, Taltz, SkyriziStelara, BimzelxTremfya, Otezla, Rinvoq

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east